American Journal of Respiratory and Critical Care Medicine

The proportion of cystic fibrosis (CF) patients dying while on the lung transplant wait list remains high; identification of such patients remains difficult. The breathing reserve index (BRI = minute ventilation/maximal voluntary ventilation) at the lactate threshold (LT) is a predictor of a pulmonary mechanical limit to incremental exercise. We hypothesized that an elevated BRI at the LT in patients with CF awaiting lung transplantation would be a predictor of wait list mortality. Forty-five consecutive patients with CF completed cardiopulmonary exercise testing as part of their pretransplant assessment. We evaluated BRI at LT, baseline demographic characteristics, pulmonary function, and other exercise parameters via Cox proportional hazards modeling. Fifteen patients died while awaiting transplant. Twenty one were transplanted, and nine still awaited transplantation. Relative risks from the multivariate model included (95% confidence interval in parentheses) BRI at LT, 17.52 (2.45–123.97); resting PaCO2, 1.29 (1.10–1.49); resting PaO2, 0.97 (0.90–1.05); and forced expiratory volume at one second as a percent of predicted, 1.19 (1.05–1.34). BRI at LT not only provided the highest point estimate of risk for wait list mortality but also identified a physiologically significant threshold value (0.70 or more) for those at risk. This measurement may allow improved timing of listing for transplantation, including consideration for living donor transplantation.

Since the mid-1980s, over 1,100 lung transplants have been performed in the United States on patients with cystic fibrosis (CF) (1). In the appropriate candidate, bilateral lung transplantation can improve pulmonary function, exercise tolerance, quality of life, and survival (2). Nevertheless, the optimal timing of referral of patients with CF for transplantation remains difficult because both the natural history of CF is highly variable (24) and transplant waiting times continue to increase (1, 3). A referral that is too late confers increased mortality while awaiting transplantation; a transplant that is too early minimizes the benefits of the procedure, while subjecting the patient to the numerous potential post-transplantation complications.

Current guidelines for cadaveric lung transplantation suggest that referral for patients with CF is appropriate when the forced expiratory volume at one second (FEV1) is 30% or less of predicted or more than 30% with rapid clinical deterioration. Other criteria include resting hypercapnia (PaCO2 > 50 mm Hg), resting hypoxemia (PaO2 < 55 mm Hg), and consideration of earlier listing for female patients (5). These guidelines are based largely on the study by Kerem and colleagues (6). In a Canadian CF population, they reported a 2-year mortality of more than 50% in patients whose FEV1 as a percent of predicted (FEV1%) fell to less than 30% for height and sex. Nevertheless, others have demonstrated a low discriminatory power of the FEV1 for predicting survival at less than 2 years (4, 7). For living donor lobar transplantation, no specific guidelines are available, other than a general consensus that patients not likely to remain a viable candidate for cadaveric transplantation should be considered. The ability to identify such patients with objective measurements should assist in the evaluation of appropriate candidates for living donor transplantation. The search for better predictors of mortality in the CF population continues.

The cardiopulmonary exercise test would seem to be ideally suited for screening patients for transplant eligibility, as it measures the patient's pulmonary and cardiovascular reserve. Prior studies have demonstrated an association between oxygen uptake at peak exercise (V·O2 max) and overall mortality in CF (8, 9). We investigated the role of a novel marker of exercise tolerance, the breathing reserve index (BRI) at the lactate threshold (LT), in patients with CF awaiting lung transplantation. The BRI at LT is defined as the minute ventilation (V·e)/maximal voluntary ventilation (MVV) at the LT (10). When measured at the LT, an elevated BRI may be a more pure, reproducible, less effort-dependent index of deranged pulmonary mechanics (10), as it is measured during a submaximal realm of exercise before the sustained increase in blood lactate and ventilatory drive that is thought to be related to circulatory and skeletal muscle dysfunction (11). We hypothesized that those CF patients with an elevated BRI at LT would be at increased risk for death while on the transplant wait list.

Study Population

Between November 1990 and March 1997, 51 patients with the primary diagnosis of CF completed transplant evaluation at the Massachusetts General Hospital. The cardiopulmonary exercise test is a routine part of the transplantation evaluation at this institution. Four patients were lost to follow-up. Two patients had no pretransplant exercise data. Therefore, 45 patients comprise this study. These were divided into two groups: those who survived to transplantation or were alive and awaiting transplantation at the time of analysis (n = 30) and those who died awaiting transplantation (n = 15). The minimum duration of listing for analysis of those alive and awaiting transplant was 18 months, set to equal the minimum expected wait time for transplantation (2).

Procedures

The standardized pretransplant cardiopulmonary exercise test protocol used has been previously detailed (12). Briefly, measures of height, weight, and pulmonary function are followed by insertion of a radial arterial catheter. Using an upright cycle ergometer, patients cycle to exhaustion via a ramp protocol. Breath by breath expired gases and V·e are measured via metabolic cart (Med Graphics, St. Paul, MN). Heart rate, blood pressure, 12-lead electrocardiogram, and arterial blood analysis are obtained at rest, every minute during exercise, and during recovery. The analyzer method used has been previously validated (13, 14).

Data Analysis

Ventilatory and gas exchange data were averaged over contiguous 30-second intervals. V·e, oxygen uptake (V·O2), CO2 output (V·CO2), dead space/tidal volume ratio (V·d/V·t), and alveolar–arteriolar oxygen difference [P(A−a)O2] were calculated from standard formulae. MVV was calculated as FEV1 × 40 (15).

V·O2 max was defined as the highest V·O2 measured during the symptom-limited exercise test. Predicted values for maximal oxygen uptake (V·O2 max) were those of Hansen and colleagues (15). The LT was defined by the “join point” of the log–log plot of lactate concentration versus V·O2 (16). In five cases of indeterminate LT, the “V-slope” gas exchange method of determining anaerobic threshold was employed (1719). The BRI was calculated as V·e/MVV at maximum exercise (BRImax) and at the LT.

Survival analysis by Cox proportional hazards modeling was done using time to event from the initial cardiopulmonary exercise test date. Patients still awaiting transplantation were censored at the time of analysis. Initial modeling evaluated the following univariate predictors: FEV1, PaCO2, PaO2, P(A−a)O2, body mass index (BMI), sex, V·O2 max, BRImax, LT, V·d/V·t, and ventilatory equivalent for CO2 (V·e/V·CO2). BRI at LT was initially modeled as a linear variable, but threshold effects were found to be equally predictive. A threshold value of 0.70 was subsequently chosen because it represents the value associated with a pulmonary mechanical limit (12, 2022). Univariate predictors of moderate statistical significance (p values ⩽ 0.25) and those of historical significance (age, BMI, and sex) were included in the initial multivariate model. Goodness of fit testing using likelihood ratio testing allowed compilation of the final multivariate predictive model. Computations were made with the SAS statistical program (version 6.12; SAS Institute, Cary, NC). Results are expressed as relative risks and their 95% confidence intervals. A p value of less than 0.05 was considered significant.

Baseline patient characteristics are shown in Table 1

TABLE 1. Baseline characteristics at time of transplant evaluation




Died

Survived
n1530
Sex, M:F7:818:12
Age, years29.7 ± 8.228.6 ± 8.6
BMI, kg/m218.9 ± 2.618.4 ± 4.3
FEV1%21.2 ± 8.227.3 ± 10.3
P(A–a)O2, mm Hg30.9 ± 13.825.5 ± 9.3
PaO2, mm Hg*64.6 ± 9.973.3 ± 12.1
PaCO2, mm Hg*
48.8 ± 10.9
40.1 ± 5.1

* p < 0.05 between the groups.

Definition of abbreviations: BMI = body mass index; FEV1 = forced expiratory volume at one second; P(A–a)O2 = alveolar–arteriolar oxygen difference.

Values are expressed as mean ± SD. PaO2, PaCO2, and P(A–a)O2 are room air, resting values.

. Demographic data were remarkable for approximately equal age, sex, and BMI distribution in the groups. The presence of Burkholderia cepacia was also assessed. Only one patient in each of the groups developed sputum cultures positive for these bacteria. Baseline spirometric and gas exchange data are also shown on Table 1. These parameters form the basis of the nonexercise variables used in the univariate proportional hazards regression model. Both groups began with an FEV1 of less than 30% of predicted as expected based on inclusion criteria; the difference in FEV1 between the groups was not statistically significant. Resting PaO2, PaCO2, and P(A−a)O2 were assessed as markers of gas exchange. The mean time of death in the group that died was 325 days, whereas the mean wait time was 826 days for those subsequently transplanted and 823 days for those still on the wait list.

Baseline exercise data from the two patient groups are shown in Table 2

TABLE 2. Baseline exercise data at time of transplant evaluation




Died

Survived
V·O2 max, L/min 818 ± 246 987 ± 383
V·O2, max/kg15.8 ± 4.218.9 ± 5.8
LT, L/min 497 ± 143 487 ± 176
LT/kg9.7 ± 3.09.3 ± 2.8
BRImax1.11 ± 0.311.09 ± 0.19
BRI at LT0.73 ± 0.190.52 ± 0.11
V·e/V·CO241.7 ± 9.438.5 ± 8.8
V·d/V·t
40.6 ± 9.9
33.5 ± 11.1

Definition of abbreviations: BRI = breathing reserve index; BRImax = BRI at maximum exercise; LT = lactate threshold; V·CO2 = CO2 output; V·d/V·t = dead space/tidal volume ratio; V·e = minute ventilation; V·O2 = oxygen uptake.

Values are expressed as mean ± SD.

. Besides the primary predictor of interest, the BRI at LT, other exercise predictors included in the univariate proportional hazards model include V·O2 max, V·O2 max/kg/min, LT, LT/kg/min, BRImax, V·e/V·CO2 at maximal exercise and at the LT, and V·d/V·t.

Univariate time-sensitive analysis of covariates of interest is shown in Table 3

TABLE 3. Univariate survival analysis for patients with cf awaiting lung transplantation


Predictor

Relative
 Risk

p Value

95%
 Confidence Intervals
 for Risk Ratio
FEV1, L/min0.26 0.18 0.04–1.87
FEV1%0.94 0.12 0.87–1.02
PaCO2, mm Hg1.210.0001 1.09–1.33
PaO2, mm Hg0.94 0.02 0.89–0.98
P(A–a)O2, mm Hg1.05 0.09 0.99–1.11
Age, years1.00 0.97 0.99–1.00
Female sex1.46 0.49 0.49–4.35
BMI, kg/m20.98 0.90 0.79–1.23
V·O2 max, L/min1.00 0.28 0.99–1.00
V·O2 max/(kg · min)0.93 0.20 0.83–1.04
BRImax2.34 0.500.19–28.22
LT, L/min1.00 0.50 0.99–1.00
BRI at LT ⩾ 0.709.820.00052.69–35.64
V·e/V·CO2 max1.03 0.35 0.97–1.03
V·d/V·t
1.04
 0.13
 0.98–1.60

Definition of abbreviations: BMI = body mass index; BRI = breathing reserve index; CF = cystic fibrosis; FEV1 = forced expiratory volume at one second; LT = lactate threshold; P(A–a)O2 = alveolar–arteriolar oxygen difference; V·CO2 = CO2 output; V·d/V·t = dead space/tidal volume ratio; V·e = minute ventilation; V·O2 = oxygen uptake.

PaO2, PaCO2, and P(A–a)O2 are room air, resting values.

. Values are expressed as relative risk ratios, assuming a null value of one; p values and 95% confidence intervals for the relative risk ratios are also shown. In the univariate analysis, the only significant predictors of mortality in this population of pretransplant CF patients were resting PaCO2, resting PaO2, and the BRI at LT. In the univariate analysis, our predictor of interest, the BRI at LT, was highly predictive of pretransplant mortality with a relative risk of 9.82 (95% confidence interval, 2.69–35.64) at a threshold value of 0.70. Several other variables approached statistical significance. These included the FEV1, FEV1%, P(A−a)O2, V·O2 max/kg/min, and V·d/V·t. The FEV1 and P(A−a)O2 were dropped because of high collinearity with the common historic predictors of the FEV1% and the PaO2. The other covariates were included in the initial multivariate model. V·O2 max, LT, and V·e/V·CO2 were not significant (p > 0.25) in the univariate analysis and were therefore excluded in the multivariate model. Although age, sex, and BMI were also not significant, they were included in the initial multivariate model because of their historical significance and the potential for confounding of the model effects without the inclusion of these covariates.

The final multivariate analysis results are shown in Table 4

TABLE 4. Multivariate survival analysis for patients withcf awaiting lung transplantation—final cox model*


Predictor

Relative Risk

p Value

95%
 Confidence Intervals
 for Risk Ratio
BRI at LT ⩾ 0.7017.520.0042.45–123.97
PaCO2, mm Hg1.290.001 1.10–1.50
PaO2, mm Hg0.97 0.48 0.90–1.05
FEV1%
1.19
0.005
 1.05–1.34

* Model chi square = 29.7; p < 0.0001.

Definition of abbreviations: BRI = breathing reserve index; CF = cystic fibrosis; FEV1 = forced expiratory volume at one second; LT = lactate threshold.

PaO2 and PaCO2 are room air, resting values.

. This model contains three significant predictors of mortality in CF: the baseline resting PaCO2, the FEV1%, and the BRI at LT. One nonsignificant predictor whose inclusion enhanced the overall model, the baseline resting PaO2, is also included in the model. Although age, sex, BMI, V·d/V·t, and V·O2 max/kg/min were included in the initial multivariate model, they did not add predictive value and were dropped from the final model. As shown, the relative risks for the model include (95% confidence intervals in parentheses): the BRI at LT, 17.52 (2.45–123.97); PaCO2, 1.29 (1.10–1.49); PaO2, 0.97 (0.90–1.05); and FEV1%, 1.19 (1.05–1.34). It should be noted that modeling excluding the BRI at LT yielded a nonsignificant result for the relative risk of the FEV1% in both the saturated (RR of 1.11, p = 0.08) and the final (RR of 1.08, p = 0.14) models.

Our data show that an elevated BRI at LT is associated with a markedly increased relative risk of death in patients with CF awaiting lung transplantation. In both our univariate and multivariate Cox regression model, the BRI at LT was the factor displaying the highest relative risk of death. Despite its ability to predict a pulmonary mechanical limit to exercise in chronic obstructive pulmonary disease (10), this is the first demonstration, to our knowledge, of the discriminatory power of the BRI at LT in predicting mortality.

The physiologic abnormalities during exercise in patients with CF, including those pretransplant, have been well described (12, 23). There is a pulmonary mechanical limit to exercise before transplantation, implying that airway obstruction prohibits patients from generating a minute ventilation (V·e) sufficient to meet the increased metabolic demands of exercise. In general, pretransplant patients with CF also develop an early lactate acidemia (12) and thus an early LT. The presence of a pulmonary mechanical limit at such an early time during the exercise cycle implies ventilatory impairment with the mildest degree of exertion.

The physiologic basis for the use of the BRI at LT as a prognostic marker in patients with CF awaiting lung transplantation rests on the uniqueness of the BRI to measure simultaneously alterations in V·e with limitations in pulmonary mechanics (as measured by the FEV1). By definition (BRI = V·e/MVV; MVV = FEV1 × 40) any increase in V·e or decrease in FEV1 at a given time point during cardiopulmonary exercise test will result in a simultaneous increase in the BRI. The rationale for the simultaneous measurement of FEV1 and V·e in the end-stage CF population follows.

It is clear that progression of disease in CF is accompanied by decrements in the FEV1; the leading cause of mortality for these patients remains respiratory failure (24). Population-based cohort studies of individuals with CF have consistently demonstrated a survival benefit associated with increasing FEV1 (6, 7, 9, 2527). The FEV1 as a percent predicted remains a prime determinant in considering CF patients for transplantation (3, 5). Although early studies also supported the predictive value of the FEV1 in CF patients awaiting lung transplantation (28, 29), they were limited by the inclusion of very ill subjects with very short survival times. This was emphasized by Ciriaco and colleagues (28). In analyzing 67 CF patients listed for transplantation between 1990–1993, they noted a mean FEV1 of 16.8% predicted in those who died awaiting transplant and concluded that patients were being referred too late. All of the more recent studies support the notion that once the FEV1 drops below 30% predicted (the primary criteria for transplant listing [5]), its discriminatory power to predict mortality becomes poor (4, 3034). The need for other markers once patients meet this criterion for transplant listing has been noted (33). In fact, an overreliance on the FEV1 may enhance the possibility of adverse outcomes in these patients (30, 32, 34). Not unexpectedly, the FEV1% did not predict mortality among the subjects in our study. Although our final multivariate model does include the FEV1% as “significant,” inclusion of the FEV1% without BRI at LT, as would be done in any study not evaluating this unique marker, produced a nonsignificant relationship (p = 0.14) between FEV1% and mortality. Models including the BRI at LT without the FEV1, however, do maintain a significant association (p = 0.02) (data not shown). Moreover, if the predictive value of the BRI on CF mortality were solely due to the effects of FEV1, it would be expected that the BRImax would have been as predictive as the BRI at LT.

Multiple studies have also demonstrated that V·e in CF is elevated, both at rest (35, 36) and during exercise (3739). Moreover, these increases in V·e tend to parallel disease severity (38, 39). Physiologic dead space increases with worsening airflow obstruction in CF (38, 39). This has led to the hypothesis that the increased V·e noted in the CF population is a reflection of the increased dead space caused by limitations in airflow (36, 38). However, other mechanisms by which the V·e in such patients can be elevated exist. First, it has been noted that alterations in carbon dioxide chemosensitivity occur during exercise in CF resulting in an abnormally high V·e for a given alteration in V·CO2 (37). Second, although cor pulmonale has long been implicated in the prognosis of CF patients (40), it has been recently demonstrated that even subclinical pulmonary hypertension is also associated with increased mortality (41, 42). Pulmonary hypertension, in turn, has been consistently associated with an increased exercise V·e for V·CO2 (4345), in part because of its independent effect on physiologic dead space (4446). Finally, it is possible that ventilatory drive in CF may be increased secondary to alterations in skeletal muscle oxygen metabolism (4749), which have been noted even during low-level exercise. The resulting decreased intracellular pH during exercise is linearly related to increased V·e in normals and can drive ventilation independent of arterial pH even before the LT (50).

Thus, the predictive ability of the BRT at LT rests on the simultaneous incorporation of a classic measure of baseline lung function, the FEV1, with that of a broader measure of exercise capacity, the V·e, which can represent alterations in pulmonary mechanics, V/Q matching, pulmonary hypertension, and skeletal muscle oxidative metabolism.

It is likely that the finding of a relatively elevated BRI could be found at any submaximal exercise period in the patients at risk; however, the LT is a convenient, reproducible reference point of cardiopulmonary function (16, 51, 52). The LT has also been advocated as a minimum training threshold to enhance pulmonary clearance in patients with CF (53). Thus, one additional speculation for the increased mortality in patients with an elevated BRI at LT is that these patients have a decreased capability to clear secretions adequately caused by failure of pulmonary mechanics.

We have chosen a threshold level for BRI at LT of 0.70 to match reference definitions for a pulmonary mechanical limit (12, 2022). The BRI at LT was dichotomized using this definition in the univariate and multivariate analyses performed. In both the univariate and multivariate analyses, the BRI at LT yielded the highest point estimates and confidence intervals for the relative risk of death. The difference in survival of those patients at or exceeding this threshold at the time of transplant evaluation compared with those below this threshold is shown in Figure 1

. However, it should be noted that there was enough of a difference between those patients with a high BRI at LT and those with a lower one that similar results could have been obtained using alternate values for the threshold. Univariate results using varying threshold levels are shown in Table 5

TABLE 5. Univariate breathing reserve index at lactate threshold at various predictive levels: relative risk of death while awaiting lung transplantation


BRI at LT

Relative Risk

95% CI
0.504.731.04–21.20
0.6011.152.45–50.36
0.709.822.69–35.64
0.80
8.21
2.75–24.47

Definition of abbreviations: BRI = breathing reserve index; CI = confidence interval; LT = lactate threshold.

.

One criticism regarding the generation of the numerical data involved in the BRI at LT might be the inclusion of patients in whom no discrete LT was measured. In these patients, the V-slope anaerobic threshold was used as the LT point. This was true of five patients, two in the group that died awaiting transplantation and three in the group that survived. Use of this determination seems to be a conservative estimate of the LT in CF. In a study of 32 patients with CF, Nikolaizik and colleagues (53) noted that the V-slope method demonstrated lower values than the LT. Assuming that the V-slope method does underestimate the LT, this would have resulted in a lower BRI at LT for our patients in whom the LT could not be determined. Thus, the presence of an elevated BRI at the lower V-slope anaerobic threshold points appears to be a valid marker for a premature pulmonary mechanical limit.

There are other potential limitations to this study. Data collection was done retrospectively, although techniques were used to minimize errors. Overall, missing data were small, and analyses with and without adjustments for missing data did not alter results. Numerically, this study was relatively small (45 patients analyzed) and may not have been sufficiently powered to allow for significance among some of the covariates. Sample size may have also led to false positives because of the number of covariates included in the initial analysis. However, the strength of the association of our primary outcome of interest, as well as the historical precedence of our other significant predictors in our multivariate analysis, lends credence to our conclusions.

In summary, an elevated BRI at LT represents reduced pulmonary mechanical reserve at low-level exercise, likely caused by a combination of increased ventilatory demand and decreased capacity. We have found that an elevated BRI at LT is highly predictive of mortality in patients with CF awaiting lung transplantation. The presence of an overt threshold level that distinguishes between those at risk for wait list mortality and those likely to survive to transplantation makes this marker unique. Use of this measurement may facilitate better prioritization of transplant listing, addressing the concern about the poor discriminatory ability of the FEV1 alone. It may also allow patients at risk for premature deaths to contemplate other options, such as living donor transplantation.

This work was supported by the American Heart Association (96-50406; D. S.) and the National Institutes of Health (K24: HL04022-02) and also in part by the Nirenberg Center for Advanced Lung Disease and the Levi Montiero Lung Transplant Fund.

1. U.S. Department of Health and Human Services. United Network for Organ Sharing: 2000 annual report of the U.S. scientific registry for transplant recipients and the organ procurement and transplantation network: transplant data: 1990–1999. Rockville, MD: Health Resources and Services Administration; 2000.
2. Zuckerman JB, Kotloff RM. Lung transplantation for cystic fibrosis. Clin Chest Med 1998;19:535–554.
3. Yankaskas JR, Mallory GB Jr. Lung transplantation in cystic fibrosis: consensus conference statement. Chest 1998;113:217–226.
4. Milla CE, Warwick WJ. Risk of death in cystic fibrosis patients with severely compromised lung function. Chest 1998;113:1230–1234.
5. International guidelines for the selection of lung transplant candidates: the American Society for Transplant Physicians (ASTP)/American Thoracic Society (ATS)/European Respiratory Society (ERS)/International Society for Heart and Lung Transplantation (ISHLT). Am J Respir Crit Care Med 1998;158:335–339.
6. Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992;326:1187–1191.
7. Matouk E, Ghezzo RH, Gruber J, Hidvegi R, Gray-Donald K. Internal consistency reliability and predictive validity of a modified N. Huang clinical scoring system in adult cystic fibrosis patients. Eur Respir J 1997;10:2004–2013.
8. Nixon PA, Orenstein DM, Kelsey SF, Doershuk CF. The prognostic value of exercise testing in patients with cystic fibrosis. N Engl J Med 1992;327:1785–1788.
9. Moorcroft AJ, Dodd ME, Webb AK. Exercise testing and prognosis in adult cystic fibrosis. Thorax 1997;52:291–293.
10. Medoff BD, Oelberg DA, Kanarek DJ, Systrom DM. Breathing reserve at the lactate threshold to differentiate a pulmonary mechanical from cardiovascular limit to exercise. Chest 1998;113:913–918.
11. Casaburi R, Patessio A, Ioli F, Zanaboni S, Donner CF, Wasserman K. Reductions in exercise lactic acidosis and ventilation as a result of exercise training in patients with obstructive lung disease. Am Rev Respir Dis 1991;143:9–18.
12. Oelberg DA, Systrom DM, Markowitz DH, Zorb SL, Wright C, Wain JC, Ginns LC. Exercise performance in cystic fibrosis before and after bilateral lung transplantation. J Heart Lung Transplant 1998;17:1104–1112.
13. Kelman GR. Digital computer subroutine for the conversion of oxygen tension into saturation. J Appl Physiol 1966;21:1375–1376.
14. Beaver WL, Wasserman K, Whipp BJ. On-line computer analysis and breath-by-breath graphical display of exercise function tests. J Appl Physiol 1973;34:128–132.
15. Hansen JE, Sue DY, Wasserman K. Predicted values for clinical exercise testing. Am Rev Respir Dis 1984;129:S49–S55.
16. Beaver WL, Wasserman K, Whipp BJ. Improved detection of lactate threshold during exercise using a log-log transformation. J Appl Physiol 1985;59:1936–1940.
17. Beaver WL, Wasserman K, Whipp BJ. A new method for detecting anaerobic threshold by gas exchange. J Appl Physiol 1986;60:2020–2027.
18. Wasserman K, Hansen JE, Sue DY, Casaburi R. Principles of exercise testing and interpretation, 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 1999.
19. Zeballos RJ, Weisman IM. Behind the scenes of cardiopulmonary exercise testing. Clin Chest Med 1994;15:193–213.
20. Weber KT. Principles and applications of cardiopulmonary exercise testing. In: Fishman AP, editor. Fishman's pulmonary diseases and disorders, 3rd ed. New York: McGraw-Hill; 1998. p. 575–588.
21. Fishman RS, Systrom DM. Preoperative cardiopulmonary exercise testing: determining the limit to exercise and predicting outcome after thoracotomy. J Cardiothorac Vasc Anesth 1991;5:614–626.
22. Russell SD, McNeer FR, Higginbotham MB. Exertional dyspnea in heart failure: a symptom unrelated to pulmonary function at rest or during exercise: Duke University Clinical Cardiology Studies (DUCCS) Exercise Group. Am Heart J 1998;135:398–405.
23. Shah AR, Gozal D, Keens TG. Determinants of aerobic and anaerobic exercise performance in cystic fibrosis. Am J Respir Crit Care Med 1998;157:1145–1150.
24. Walsh MJ, Smith AE. Cystic fibrosis. Sci Am 1995;273:52–59.
25. Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970–1989. Am J Epidemiol 1996;143:1007–1017.
26. Grasemann H, Wiesemann HG, Ratjen F. The importance of lung function as a predictor of 2-year mortality in mucoviscidosis. Pneumologie 1995;49:466–469.
27. Hayllar KM, Williams SG, Wise AE, Pouria S, Lombard M, Hodson ME, Westaby D. A prognostic model for the prediction of survival in cystic fibrosis. Thorax 1997;52:313–317.
28. Ciriaco P, Egan TM, Cairns EL, Thompson JT, Detterbeck FC, Paradowski LJ. Analysis of cystic fibrosis referrals for lung transplantation. Chest 1995;107:1323–1327.
29. Sharples L, Hathaway T, Dennis C, Caine N, Higenbottam T, Wallwork J. Prognosis of patients with cystic fibrosis awaiting heart and lung transplantation. J Heart Lung Transplant 1993;12:669–674.
30. Venuta F, Rendina EA, De Giacomo T, Quattrucci S, Vizza D, Ciccone AM, Guarino E, Della Rocca G, Ricci C. Timing and priorities for cystic fibrosis patients candidates to lung transplantation. Eur J Pediatr Surg 1998;8:274–277.
31. Augarten A, Akons H, Aviram M, Bentur L, Blau H, Picard E, Rivlin J, Miller MS, Katznelson D, Szeinberg A, et al. Prediction of mortality and timing of referral for lung transplantation in cystic fibrosis patients. Pediatr Transplant 2001;5:339–342.
32. Vizza CD, Yusen RD, Lynch JP, Fedele F, Alexander Patterson G, Trulock EP. Outcome of patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med 2000;162:819–825.
33. Snell GI, Bennetts K, Bartolo J, Levvey B, Griffiths A, Williams T, Rabinov M. Body mass index as a predictor of survival in adults with cystic fibrosis referred for lung transplantation. J Heart Lung Transplant 1998;17:1097–1103.
34. Doershuk CF, Stern RC. Timing of referral for lung transplantation for cystic fibrosis: overemphasis on FEV1 may adversely affect overall survival. Chest 1999;115:782–787.
35. Bell SC, Saunders MJ, Elborn JS, Shale DJ. Resting energy expenditure and oxygen cost of breathing in patients with cystic fibrosis. Thorax 1996;51:126–131.
36. Hirsch JA, Zhang SP, Rudnick MP, Cerny FJ, Cropp GJ. Resting oxygen consumption and ventilation in cystic fibrosis. Pediatr Pulmonol 1989;6:19–26.
37. Pianosi P, Wolstein R. Carbon dioxide chemosensitivity and exercise ventilation in healthy children and in children with cystic fibrosis. Pediatr Res 1996;40:508–513.
38. Cerny FJ, Pullano TP, Cropp GJ. Cardiorespiratory adaptations to exercise in cystic fibrosis. Am Rev Respir Dis 1982;126:217–220.
39. Cropp GJ, Pullano TP, Cerny FJ, Nathanson IT. Exercise tolerance and cardiorespiratory adjustments at peak work capacity in cystic fibrosis. Am Rev Respir Dis 1982;126:211–216.
40. Stern RC, Borkat G, Hirschfeld SS, Boat TF, Matthews LW, Liebman J, Doershuk CF. Heart failure in cystic fibrosis: treatment and prognosis of cor pulmonale with failure of the right side of the heart. Am J Dis Child 1980;134:267–272.
41. Fraser KL, Tullis DE, Sasson Z, Hyland RH, Thornley KS, Hanly PJ. Pulmonary hypertension and cardiac function in adult cystic fibrosis: role of hypoxemia. Chest 1999;115:1321–1328.
42. Venuta F, Rendina EA, Rocca GD, De Giacomo T, Pugliese F, Ciccone AM, Vizza CD, Coloni GF. Pulmonary hemodynamics contribute to indicate priority for lung transplantation in patients with cystic fibrosis. J Thorac Cardiovasc Surg 2000;119:682–689.
43. D'Alonzo GE, Gianotti LA, Pohil RL, Reagle RR, DuRee SL, Fuentes F, Dantzker DR. Comparison of progressive exercise performance of normal subjects and patients with primary pulmonary hypertension. Chest 1987;92:57–62.
44. Reybrouck T, Mertens L, Schulze-Neick I, Austenat I, Eyskens B, Dumoulin M, Gewillig M. Ventilatory inefficiency for carbon dioxide during exercise in patients with pulmonary hypertension. Clin Physiol 1998;18:337–344.
45. Ting H, Sun XG, Chuang ML, Lewis DA, Hansen JE, Wasserman K. A noninvasive assessment of pulmonary perfusion abnormality in patients with primary pulmonary hypertension. Chest 2001;119:824–832.
46. Otulana B, Higenbottam T. The role of physiological deadspace and shunt in the gas exchange of patients with pulmonary hypertension: a study of exercise and prostacyclin infusion. Eur Respir J 1988;1:732–737.
47. Moser C, Tirakitsoontorn P, Nussbaum E, Newcomb R, Cooper DM. Muscle size and cardiorespiratory response to exercise in cystic fibrosis. Am J Respir Crit Care Med 2000;162:1823–1827.
48. Systrom DM, Krause W, Maroni J, Oelberg DA, Gabriel A, Horvat M, Ginns LC. Exercising skeletal muscle energetics and pHi after lung transplantation for cystic fibrosis [abstract]. Am J Respir Crit Care Med 1999;159:A412.
49. de Meer K, Jeneson JA, Gulmans VA, van der Laag J, Berger R. Efficiency of oxidative work performance of skeletal muscle in patients with cystic fibrosis. Thorax 1995;50:980–983.
50. Oelberg DA, Evans AB, Hrovat MI, Pappagianopoulos PP, Patz S, Systrom DM. Skeletal muscle chemoreflex and pHi in exercise ventilatory control. J Appl Physiol 1998;84:676–682.
51. Dickhuth HH, Yin L, Niess A, Rocker K, Mayer F, Heitkamp HC, Horstmann T. Ventilatory, lactate-derived and catecholamine thresholds during incremental treadmill running: relationship and reproducibility. Int J Sports Med 1999;20:122–127.
52. Pfitzinger P, Freedson PS. The reliability of lactate measurements during exercise. Int J Sports Med 1998;19:349–357.
53. Nikolaizik WH, Knopfli B, Leister E, de Boer P, Sievers B, Schoni MH. The anaerobic threshold in cystic fibrosis: comparison of V-slope method, lactate turn points, and Conconi test. Pediatr Pulmonol 1998;25:147–153.
Correspondence and requests for reprints should be addressed to Leo C. Ginns, M.D., Massachusetts General Hospital, Lung Transplantation Program, Pulmonary and Critical Care Unit, Bigelow 808, Boston, MA 02114. E-mail:

Related

No related items
American Journal of Respiratory and Critical Care Medicine
165
12

Click to see any corrections or updates and to confirm this is the authentic version of record